- Home
- MAIA vs IKNA Comparison
MAIA vs IKNA Comparison
Compare MAIA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- IKNA
- Stock Information
- Founded
- MAIA 2018
- IKNA 2016
- Country
- MAIA United States
- IKNA United States
- Employees
- MAIA N/A
- IKNA N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- IKNA Health Care
- Exchange
- MAIA Nasdaq
- IKNA Nasdaq
- Market Cap
- MAIA 46.7M
- IKNA 61.8M
- IPO Year
- MAIA 2022
- IKNA 2021
- Fundamental
- Price
- MAIA $1.82
- IKNA $1.32
- Analyst Decision
- MAIA
- IKNA Strong Buy
- Analyst Count
- MAIA 0
- IKNA 1
- Target Price
- MAIA N/A
- IKNA $4.00
- AVG Volume (30 Days)
- MAIA 549.7K
- IKNA 59.9K
- Earning Date
- MAIA 08-08-2025
- IKNA 08-07-2025
- Dividend Yield
- MAIA N/A
- IKNA N/A
- EPS Growth
- MAIA N/A
- IKNA N/A
- EPS
- MAIA N/A
- IKNA N/A
- Revenue
- MAIA N/A
- IKNA N/A
- Revenue This Year
- MAIA N/A
- IKNA N/A
- Revenue Next Year
- MAIA N/A
- IKNA N/A
- P/E Ratio
- MAIA N/A
- IKNA N/A
- Revenue Growth
- MAIA N/A
- IKNA N/A
- 52 Week Low
- MAIA $1.40
- IKNA $0.97
- 52 Week High
- MAIA $4.24
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- MAIA 53.36
- IKNA 51.66
- Support Level
- MAIA $1.60
- IKNA $1.31
- Resistance Level
- MAIA $2.03
- IKNA $1.36
- Average True Range (ATR)
- MAIA 0.12
- IKNA 0.04
- MACD
- MAIA 0.02
- IKNA -0.01
- Stochastic Oscillator
- MAIA 58.14
- IKNA 13.61
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.